Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Review Article

FLT3 Inhibitors in the Management of Acute Myeloid Leukemia

Author(s): E. Zappone*, M. Defina, L. Aprile, G. Bartalucci, A. Gozzetti and M. Bocchia

Volume 17, Issue 8, 2017

Page: [1028 - 1032] Pages: 5

DOI: 10.2174/1871520616666161010162737

Price: $65

Abstract

In recent years there has been a great improvement in molecular characterization of acute myeloid leukemia (AML) allowing the stratification of patients in different rate of risk. Patients with FLT3 mutated AML have poor prognosis because of resistance to induction chemotherapy or early relapse. Several first and second generation molecules, able to inhibit FLT3 signaling have been developed and many single agent or combination studies are ongoing. Of these, quizartinib seems to have the best clinical activity. Unfortunately, resistance to FLT3 inhibitors has been observed and many scientists are currently investigating new strategy to restore sensitivity to FLT3 inhibitors.

Keywords: Acute myeloid leukemia, FLT3, inhibitors, molecular target, prognosis.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy